CND Life Sciences’ Syn-One® Biomarker Services Used for Novel Parkinson’s Disease Endpoint in Phase 2 Drug Trial
/PRNewswire/ — CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated…
November 11, 2025